We've built a new version of this page with an interactive 3D viewer. Try it out in beta and help us improve:

› 3lmi

X-ray diffraction
2.2Å resolution

Crystal Structure of the Inactive Alpha-kinase Domain of Myosin Heavy Chain Kinase A (D766A) complex with ATP

Released:
DOI: 10.2210/pdb3lmi/pdb
Model geometry
Fit model/data
PDB entry 3lmi coloured by chain, front view.
PDB entry 3lmi coloured by chain, side view.
PDB entry 3lmi coloured by chain, top view.
Source organism: Dictyostelium discoideum
Primary publication:
Crystal structure of the alpha-kinase domain of Dictyostelium myosin heavy chain kinase A.
Ye Q, Crawley SW, Yang Y, Côté GP, Jia Z
Sci Signal 3 ra17 (2010)
PMID: 20197546

Function and Biology Details

Reaction catalysed: 
L-threonyl-[myosin heavy-chain] + ATP = O-phospho-L-threonyl-[myosinheavy-chain] + ADP + H(+).
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-154659 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Myosin heavy chain kinase A Chains: A, B, C, D
Molecule details ›
Chains: A, B, C, D
Length: 307 amino acids
Theoretical weight: 34.48 KDa
Source organism: Dictyostelium discoideum
Expression system: Escherichia coli
UniProt:
  • Canonical: P42527 (Residues: 552-841; Coverage: 25%)
Gene names: DDB_G0291231, mhckA, mhkA
Sequence domains: Alpha-kinase family
Structure domains:

Ligands and Environments

4 bound ligands:
Ligand PO4 6 x PO4
Ligand ZN 4 x ZN
Ligand MG 4 x MG
Ligand ATP 4 x ATP
No modified residues

Experiments and Validation Details

wwPDB Validation report is not available for this entry.
X-ray source: CHESS BEAMLINE F1
Spacegroup: P41
Unit cell:
a: 81.192Å b: 81.192Å c: 187.561Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.203 0.199 0.269
Expression system: Escherichia coli

Quick links

Citations

6 review citations

Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Liu et al. (2016)
5 more

7 mentions without citation

eEF2K Inhibitor Design: The Progression of Exemplary Structure-Based Drug Design.
Klupt et al. (2023)
6 more